2013 American Transplant Congress
Treatment of Renal Transplant Patients with Autologous Bone Marrow Derived Mesenchymal Stromal Cells Downregulates the Donor Specific Mixed Lymphocyte Reaction
MSCs are arising as promising tool in solid organ transplantation to down regulate alloimmune responses. Defining the function and ways to monitor its immunologic effects…2013 American Transplant Congress
Kidney Donor Risk Index Is a Good Prognostic Tool for Graft Outcomes in Deceased-Donor Kidney Transplantation with Short, Cold Ischemic Time
Background: The shortage of donor kidneys necessitates the use of expanded criteria donor (ECD) kidneys. However, prognostic tools for predicting allograft outcomes are required to…2013 American Transplant Congress
Comparison of Transumbilical and Conventional Laparoscopic Donor Nephrectomy
Forty-eight healthy voluntary renal donors between 18 and 60 years of age with BMI less than 30 who were planned for laparoscopic left side donor…2013 American Transplant Congress
Liver Transplantation: Do Senescence and Autophagy Modulate the Development of Chronic Pathology
During the past 20 years there has been a reduction in the incidence of both acute cellular rejection (ACR) and chronic ductopenic rejection following liver…2013 American Transplant Congress
Efficacy of Everolimus with Reduced Cyclosporine in Japanese De Novo Renal Transplant Recipients: 24-Month, Randomized, Multicenter Study
Introduction: Results from study A1202 showed that everolimus (EVR) plus reduced dose cyclosporine (rCsA) prevents acute rejection, preserves renal function, and reduces incidence of viral…2013 American Transplant Congress
Positive Flow Crossmatches in Renal Patients without “Detectable” Anti-Donor HLA Antibodies; Maximizing Renal Transplant Rate by Decreasing False Positive Crossmatches
HLA Laboratory and the Transplant Center, Lehigh Valley Health Network, Allentown, PA
A recurring problem in recipient selection for deceased donor renal transplantation is a positive crossmatch in a “non-donor antigen sensitized “individuals. We initiated a study…2013 American Transplant Congress
IL-33: Friend or Foe?
Introduction We hypothesize that innate inflammatory response either preexistent in the recipient or released by injured allografts during transplantation may influence graft outcome. In a…2013 American Transplant Congress
Effects of Everolimus and Tacrolimus Exposure on Efficacy and Renal Function in Liver Transplant Recipients at 24 Months in a Randomized Trial (H2304)
For the H2304 Study Group, Hamburg, Germany; Novartis Pharma AG, Basel, Switzerland
Purpose: The present analysis aims to explore the effect of everolimus (EVR) and tacrolimus (TAC) exposure on efficacy and safety events of interest in de…2013 American Transplant Congress
Everolimus-Facilitated Reduction of Tacrolimus in De Novo Liver Transplant Recipients Achieves Comparable Overall Efficacy with Fewer Biopsy-Proven Acute Rejections Versus Standard Tacrolimus: 24-Month Results of a Randomized Trial
Purpose: The H2304 (NCT00622869) study compared the efficacy and safety of concentration-controlled everolimus (EVR) to eliminate or to reduce tacrolimus (TAC) vs standard TAC (TAC-C)…2013 American Transplant Congress
Lack of Clinical Factors Increasing Quantitative Interstitial Fibrosis after Renal Transplantation under a Lower Target Trough Strategy of Tacrolimus
INTRODUCTION AND OBJECTIVES: Chronic allograft injury is a multi-factorial process based on immunologic and non-immunologic factors. Patients with the CYP3A5*3/*3 genotype (non-expressers) require a lower…
- « Previous Page
- 1
- …
- 138
- 139
- 140
- 141
- 142
- …
- 178
- Next Page »